Next-generation CAR T cell therapies for glioblastoma.
Joshua D BernstockJakob V E GerstlPablo A ValdésGregory K FriedmanE Antonio ChioccaPublished in: Science translational medicine (2024)
Interim results from two phase 1 trials demonstrate progress in the use of chimeric antigen receptor (CAR) T cell therapy for recurrent glioblastoma (GBM).